newsfilter
← Latest News
GlobeNewswire·

Oncotelic Announces PDAOAI Identification of a Four-Gene Liver Cancer Signature

OTLC
  • Oncotelic Therapeutics announced a peer-reviewed study in Biomedicines demonstrating its AI-powered PDAOAI platform identified a four-gene prognostic signature for hepatocellular carcinoma (HCC).
  • The study utilized the company's patented Partitioned Literature Aggregation (PLA) algorithm combined with transcriptomic & survival analysis to uncover the signature without prompt engineering.
  • The four-gene signature comprises FKBP1A, EIF4E, RRAGC, & PPARGC1A, with survival associations validated in a Japanese HCC cohort of 203 patients.
  • Findings define patient stratification for clinical trials of Sapu003, an intravenous formulation of the mTOR inhibitor everolimus.
  • Saran Saund, Chief Business Officer, stated PLA provided validated biomarkers to restart the stalled development of everolimus for liver cancer treatment.
  • The research approach mirrors recent AI collaborations at Anthropic & OpenAI that use parallel agent investigations to identify overlooked biological systems.
  • Oncotelic plans to scale its PDAOAI platform to approximately 100 billion biological vectors for genetic & protein research.
  • PLA is patent pending globally with an issued patent in Mexico.
  • The BIO REBOOT initiative allows external teams to submit research questions to the PDAOAI community for potential startup funding & development support.
  • PDAOAI currently indexes approximately 29 million PubMed abstracts & uses the Fastbot/Membot interface for hypothesis generation.
  • The study was presented by Saund on October 22, 2026, at the 22nd Drug Discovery Strategic Summit in Millbrae, California.
  • The full paper is available open access in Biomedicines, Volume 14, Issue 11, article 2438, with DOI 10.3390/biomedicines14112438.